Pharvaris' Deucrictibant Phase 3 Data Published in The Lancet, Showing Rapid HAE Attack Resolution
PHVS sits 49% above its 52-week low of $20.65.
Summary
Pharvaris announced publication of RAPIDe-3 Phase 3 results in The Lancet, a top-tier medical journal. The study met its primary endpoint and all 11 secondary endpoints with high statistical significance, showing deucrictibant IR rapidly ended attack progression and accelerated complete symptom resolution versus placebo. Most attacks were controlled with a single oral capsule, with no safety signals. Results were consistent across subgroups, including HAE with normal C1 inhibitor and non-severe laryngeal attacks. This publication follows positive topline data from the CHAPTER-3 prophylactic study in September and supports the ongoing NDA review with a PDUFA date of April 23, 2027. The data strengthen the case for deucrictibant as the first oral bradykinin B2 receptor antagonist for on-demand HAE treatment.
At the time of this announcement, PHVS was trading at $30.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $20.65 to $43.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.